The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Management of Insomnia | New England Journal of Medicine
Jul 17, 2024 · Insomnia is common and frequently occurs with other disorders. First-line cognitive behavioral therapy with or without medication can produce rapid, sustained alleviation of insomnia symptoms.
The Emerging Threat of H5N1 to Human Health | New England …
Dec 31, 2024 · Against this background, more humans have come into contact with HPAI A(H5N1). Investigators now report in the Journal a series of human cases from the United States and Canada. 2,3 The former ...
Hydrocortisone in Severe Community-Acquired Pneumonia | New …
Mar 21, 2023 · New perspectives on community-acquired pneumonia in 388 406 patients: results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009;64:1062-1069. Crossref
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type …
Oct 23, 2020 · Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH …
Feb 7, 2024 · From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National ...
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without ...
Jun 14, 2024 · Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of ...
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell …
Sep 13, 2024 · Durvalumab is a selective, high-affinity human IgG1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1), blocking its interaction with programmed death 1 (PD-1) and CD80 on ...
Medical Articles - The New England Journal of Medicine
Explore the index of articles published by the New England Journal of Medicine, from original research to videos in clinical medicine and more.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after ...